• Je něco špatně v tomto záznamu ?

Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis

S. Bringhen, L. Pour, V. Vorobyev, F. Vural, K. Warzocha, L. Benboubker, Y. Koh, V. Maisnar, L. Karlin, M. Pavic, F. Campana, S. Le Guennec, F. Menas, H. van de Velde, PG. Richardson

. 2021 ; 104 (-) : 106576. [pub] 20210329

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21025807

Patients with relapsed/refractory multiple myeloma (RRMM) experience several relapses, and become refractory to successive therapies. In the ICARIA-MM trial (NCT02990338), isatuximab plus pomalidomide-dexamethasone prolonged median progression-free survival (PFS) in patients with RRMM. This subgroup analysis of ICARIA-MM assessed the treatment benefit of isatuximab by prior lines of therapy and refractory status. A total of 307 patients were randomized to isatuximab-pomalidomide-dexamethasone (n = 154) or pomalidomide-dexamethasone (n = 153). Isatuximab (10 mg/kg intravenously) was given weekly in the first 28-day cycle, then every other week. Standard pomalidomide-dexamethasone doses were given. PFS was assessed by prior lines and refractory status. Overall, 102 (66 %) patients receiving isatuximab-pomalidomide-dexamethasone and 101 (66 %) patients receiving pomalidomide-dexamethasone had received 2-3 prior lines; 52 (34 %) and 52 (34 %) had received >3 prior lines, respectively. Median PFS was higher with isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone for patients who received 2-3 prior lines of therapy (12.3 vs. 7.8 months) and >3 prior lines of therapy (9.4 vs. 4.3 months). Median PFS was higher with isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone for patients who were lenalidomide-refractory (11.4 vs. 5.6 months), lenalidomide-refractory at last line (11.6 vs. 5.7 months), refractory to a proteasome inhibitor (PI) (11.4 vs. 5.6 months), and double-refractory (11.2 vs. 4.8 months). Overall response rate (ORR) in patients receiving isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone was 59.0 % versus 31.4 % in lenalidomide-refractory; 60.2 % versus 32.2 % in PI-refractory; and 58.6 % versus 29.9 % in double-refractory patients. Isatuximab-pomalidomide-dexamethasone improved PFS and ORR regardless of prior lines of therapy or refractory status, consistent with the benefit in the overall population.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21025807
003      
CZ-PrNML
005      
20211026133500.0
007      
ta
008      
211013s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.leukres.2021.106576 $2 doi
035    __
$a (PubMed)33839618
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Bringhen, Sara $u Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Turin, Italy. Electronic address: sarabringhen@yahoo.com
245    10
$a Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis / $c S. Bringhen, L. Pour, V. Vorobyev, F. Vural, K. Warzocha, L. Benboubker, Y. Koh, V. Maisnar, L. Karlin, M. Pavic, F. Campana, S. Le Guennec, F. Menas, H. van de Velde, PG. Richardson
520    9_
$a Patients with relapsed/refractory multiple myeloma (RRMM) experience several relapses, and become refractory to successive therapies. In the ICARIA-MM trial (NCT02990338), isatuximab plus pomalidomide-dexamethasone prolonged median progression-free survival (PFS) in patients with RRMM. This subgroup analysis of ICARIA-MM assessed the treatment benefit of isatuximab by prior lines of therapy and refractory status. A total of 307 patients were randomized to isatuximab-pomalidomide-dexamethasone (n = 154) or pomalidomide-dexamethasone (n = 153). Isatuximab (10 mg/kg intravenously) was given weekly in the first 28-day cycle, then every other week. Standard pomalidomide-dexamethasone doses were given. PFS was assessed by prior lines and refractory status. Overall, 102 (66 %) patients receiving isatuximab-pomalidomide-dexamethasone and 101 (66 %) patients receiving pomalidomide-dexamethasone had received 2-3 prior lines; 52 (34 %) and 52 (34 %) had received >3 prior lines, respectively. Median PFS was higher with isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone for patients who received 2-3 prior lines of therapy (12.3 vs. 7.8 months) and >3 prior lines of therapy (9.4 vs. 4.3 months). Median PFS was higher with isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone for patients who were lenalidomide-refractory (11.4 vs. 5.6 months), lenalidomide-refractory at last line (11.6 vs. 5.7 months), refractory to a proteasome inhibitor (PI) (11.4 vs. 5.6 months), and double-refractory (11.2 vs. 4.8 months). Overall response rate (ORR) in patients receiving isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone was 59.0 % versus 31.4 % in lenalidomide-refractory; 60.2 % versus 32.2 % in PI-refractory; and 58.6 % versus 29.9 % in double-refractory patients. Isatuximab-pomalidomide-dexamethasone improved PFS and ORR regardless of prior lines of therapy or refractory status, consistent with the benefit in the overall population.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a humanizované monoklonální protilátky $x aplikace a dávkování $x škodlivé účinky $7 D061067
650    _2
$a protokoly protinádorové kombinované chemoterapie $x aplikace a dávkování $x škodlivé účinky $7 D000971
650    _2
$a dexamethason $x aplikace a dávkování $x škodlivé účinky $7 D003907
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mnohočetný myelom $x farmakoterapie $x mortalita $7 D009101
650    _2
$a prospektivní studie $7 D011446
650    _2
$a míra přežití $7 D015996
650    _2
$a thalidomid $x aplikace a dávkování $x škodlivé účinky $x analogy a deriváty $7 D013792
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Pour, Ludek $u Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Vorobyev, Vladimir $u S.P. Botkin Hospital, Moscow, Russia
700    1_
$a Vural, Filiz $u Ege University Medical Faculty, Izmir, Turkey
700    1_
$a Warzocha, Krzysztof $u Instytut Hematologii i Transfuzjologii, Warsaw, Poland
700    1_
$a Benboubker, Lotfi $u Department of Hematology, University Hospital Tours, Tours, France
700    1_
$a Koh, Youngil $u Seoul National University Hospital, Seoul, South Korea
700    1_
$a Maisnar, Vladimir $u Charles University Hospital, Hradec Kralove, Czech Republic
700    1_
$a Karlin, Lionel $u Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre-Benite, France
700    1_
$a Pavic, Michel $u University of Sherbrooke, Sherbrooke, QC, Canada
700    1_
$a Campana, Frank $u Sanofi, Cambridge, MA, USA
700    1_
$a Le Guennec, Solenn $u Sanofi R&D, Vitry-sur-Seine, France
700    1_
$a Menas, Fatima $u Aixial (for Sanofi), Boulogne-Billancourt, France
700    1_
$a van de Velde, Helgi $u Sanofi, Cambridge, MA, USA
700    1_
$a Richardson, Paul G $u Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
773    0_
$w MED00003141 $t Leukemia research $x 1873-5835 $g Roč. 104, č. - (2021), s. 106576
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33839618 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026133506 $b ABA008
999    __
$a ok $b bmc $g 1714728 $s 1146314
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 104 $c - $d 106576 $e 20210329 $i 1873-5835 $m Leukemia research $n Leuk Res $x MED00003141
LZP    __
$a Pubmed-20211013
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace